QIAGEN N.V. : Notification and public disclosure of transactions by persons
March 12, 2021 at 04:09 pm EST
Share
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
12.03.2021 / 22:08
The issuer is solely responsible for the content of this announcement.
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name
Title:
Prof. Dr.
First name:
Ross L.
Last name(s):
Levine
2. Reason for the notification
a) Position / status
Position:
Member of the administrative or supervisory body
b) Amendment
Subsequent to the grant release of 3,946 Restricted Stock Units on February 28, 2021, receipt of 1,978 Common Shares upon net share settlement.
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
QIAGEN N.V.
b) LEI
54930036WK3GMCN17Z57
4. Details of the transaction(s)
a) Description of the financial instrument, type of instrument, identification code
Type:
Share
ISIN:
NL0012169213
b) Nature of the transaction
Release of 3,946 Restricted Stock Units on February 28, 2021 based on grant made on February 28, 2018.
Exercise Price: $0.00. Closing price on February 26, 2021: $50.00.
Subsequent to the grant release, receipt of 1,781 Common Shares upon net share settlement wherein a number of Common Shares are withheld by the Company to cover related expenses (such as taxes and transaction costs based on share price on vesting date).
Transaction linked to the exercise of share option programmes
c) Price(s) and volume(s)
Price(s)
Volume(s)
not numberable
not numberable
d) Aggregated information
Price
Aggregated volume
not numberable
not numberable
e) Date of the transaction
2021-02-28; UTC+1
f) Place of the transaction
Outside a trading venue
12.03.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN N.V. 
